Pyridoxamine — Advanced Glycation (AGE) Cross-Link Inhibition

#44

For years, targeting advanced glycation end products (AGEs) was seen as a holy grail for arresting diabetic nephropathy (diabetic kidney disease). Preclinical data were glowing: oral pyridoxamine dihydrochloride (Pyridorin), a vitamin B6 derivative developed by NephroGenex, routinely rescued renal function in diabetic rat models by scavenging toxic carbonyls and reactive oxygen species.

However, translating benchtop success to bedside reality proved to be a multi-million-dollar bottleneck.

The Trial and the Flop

The hype hit a wall during Phase 2/3 evaluations. In a pivotal 1-year, multi-center, randomized controlled trial, investigators evaluated the efficacy of Pyridorin (150 mg and 300 mg BID) against a placebo in patients with Type 2 diabetic nephropathy who were already stabilized on standard-of-care ACE inhibitors or ARBs.

The readouts were unforgiving:

  • Primary Endpoint Failure: Pyridorin failed to demonstrate any statistically significant reduction in the progression of serum creatinine concentrations compared to the placebo at 52 weeks.
  • Secondary Deficits: The drug showed no meaningful impact on estimated glomerular filtration rate (eGFR) decline or overall proteinuria (urine protein-to-creatinine ratios remained virtually unaltered).

The Post-Mortem

Subgroup analyses threw a minor lifeline, suggesting that patients in the lowest tertile of baseline serum creatinine (those with earlier, less severe kidney impairment) might retain some therapeutic benefit. Armed with these post-hoc insights, a Phase 3 study (PIONEER-CSG-17) was designed under an FDA Special Protocol Assessment to target earlier-stage cohorts with strict blood pressure stabilization windows.

Unfortunately, the clinical momentum stalled out entirely. Beset by financial distress, NephroGenex ultimately filed for bankruptcy, and the once-promising AGE-inhibitor joined a long list of metabolic pipeline casualties. The Pyridorin saga remains a textbook warning that robust biomarker reduction in animals does not automatically safeguard human nephrons.

1 Like
#45

It’s a shame this was the end of pyridoxamine studies in humans. This trial was doomed to fail IMO. Pyridoxamine doesn’t reverse glycation (it’s not a crosslink breaker) it slows down glycation. Glycation is a very slow progress that slowly accumulates and causes damage over years and decades. If pyridoxamine worked you would not expect to see reversal and improvement in kidney disease. Rather you would expect to see a slowdown of further decline, something that might take perhaps 5 years to become noticeable between groups in a trial.

It’s such a shame that this drug company tried to designate pyridoxamine as a drug, thus effectively getting it banned as a supplement in the US, and then fails to test it properly, and now it remains stuck being categorized as a drug in the USA.

2 Likes
#46

It appears research-grade pyridoxamine is unfit for human consumption. The quality control is simply inadequate, even from top-tier brands like Merck. Based on the human trials I checked, the oral pyridoxamine administered is all synthesized in-house by university labs. Sigma-Aldrich chemicals are kept strictly for analytical use.

2.1 Chemicals
Pyridoxine (PN, ≥98%), D3-pyridoxine (D3-PN, ≥98%), pyridoxamine-5′-phosphate (PMP, ≥98%), pyridoxal (PL, ≥99%), pyridoxal-5′-phosphate (PLP, ≥98%) and perchloric acid (PCA, 70%) were obtained from Sigma–Aldrich (Steinheim, Germany). D3-pyridoxamine (D3-PM) was obtained from Cambridge Isotope Laboratories (Andover, USA). D3-pyridoxal-5′-phosphate (D3-PLP) was obtained from Buchem (Apeldoorn, The Netherlands). Tridecafluoroheptanoic acid (TDFHA, >98%) was obtained from Alfa Aesar (Kandel, Germany). Water and acetonitrile (ULC/MS quality) were obtained from Biosolve Chimie (Dieuze, France).

Pyridoxamine (pyridoxamine∙HCl) was obtained from Tohoku University School of Medicine (Sendai, Japan) @RapAdmin

#47

This is certainly a supplement I would like to take.

Unfortunately, real pyridoxamine is hard to get. The products on Amazon that claim to be B6 pyridoxamine are not actually true pyridoxamine.

It is, of course, available from our usual Indian suppliers under the name of Renosave Forte. It’s a prescription drug that combines pyridoxamine with NAC. The strongest dose I can find is 75 mg of pyridoxamine with 300 mg of NAC. This is okay with me because I take NAC and don’t mind taking more.

The dosage range is:

In the major human trials investigating pyridoxamine (under the drug name Pyridorin) for microvascular protection and diabetic kidney disease, researchers targeted the following dosage ranges:

Moderate Dose: 150 mg taken twice daily (300 mg total per day).

High Dose (Phase 3 Standard): 300 mg taken twice daily (600 mg total per day).

In these studies, a total daily intake of 300 mg to 600 mg was identified as the therapeutic window. This concentration was necessary to effectively circulate in the bloodstream, scavenge reactive carbonyls, and inhibit the formation of Advanced Glycation End-products (AGEs) before they could cross-link with tissue.

"When you search for “pyridoxamine” on Amazon, their algorithm automatically substitutes standard B6 products because true pyridoxamine is not legally available as an over-the-counter supplement in the United States.

In 2009, the FDA banned the sale of pyridoxamine as a dietary supplement. This occurred because a pharmaceutical company was running Phase II clinical trials on it as an investigational new drug (under the name Pyridorin) to treat diabetic kidney disease. Under FDA regulations, once a substance is formally investigated as a new prescription drug, it loses its supplement status.

Because of this regulatory barrier, you will not find genuine pyridoxamine on mainstream retail sites. People targeting AGE inhibition and matrix cross-linking usually have to shift to alternative, legally available carbonyl scavengers."

Obtaining true pyridoxamine for personal consumption in the United States is virtually impossible through standard retail channels due to the 2009 FDA ruling that classified it as an investigational new drug.

Here is the current reality of trying to source it:

Mainstream Retailers

You will not find pyridoxamine at local pharmacies, vitamin shops, or online retailers. If you search for it on platforms like Amazon or iHerb, their algorithms will automatically redirect you to standard Vitamin B6 (pyridoxine) or P-5-P. As previously noted, these do not possess the same AGE-inhibiting chemical structure.

The Unique Mechanism of Pyridoxamine

Vascular matrix stiffening—a primary driver of reduced microvascular compliance—is largely caused by the accumulation of AGEs and Advanced Lipoxidation End-products (ALEs). These form when reactive carbonyl species (RCS), such as methylglyoxal, biochemically attack the amino groups of structural proteins like collagen and elastin, creating rigid cross-links in the extracellular matrix.

Pyridoxamine is uniquely equipped to intervene in this process due to its chemical structure:

  • Carbonyl Scavenging: Pyridoxamine contains a highly reactive nucleophilic amino group. This allows it to act as a potent “carbonyl scavenger.” It binds directly to pathogenic reactive carbonyls before they can cross-link with vascular proteins, effectively neutralizing them.
  • Metal Ion Chelation: Pyridoxamine chelates catalytic metal ions (like copper and iron) that are necessary for the oxidative chemistry that drives AGE/ALE formation.
  • Clinical Focus: Because of this specific mechanism, pyridoxamine was heavily investigated as a pharmaceutical therapy (under the name Pyridorin) specifically to prevent vascular and renal damage by inhibiting AGE formation.

Pyridoxamine treatment ameliorates large artery stiffening and cerebral artery endothelial dysfunction in old mice

Protective Effects of Pyridoxamine Supplementation in the Early Stages of Diet-Induced Kidney Dysfunction

How Does Pyridoxamine Inhibit the Formation of Advanced Glycation End Products? The Role of Its Primary Antioxidant Activity

Pyridorin in Type 2 Diabetic Nephropathy

Pyridoxamine improves survival and limits cardiac dysfunction after MI

The effect of aminoguanidine (AG) and pyridoxamine (PM) on ageing human cortical bone

4 Likes
#48

Thanks for sharing. I completely forgot that India is such a treasure trove for this kind of stuff.

#49

Looking at the *IndiaMart website what seems available are Renosave Forte tablets of NAC 300mg + pyridoxamine 75mg
Requesting that, I was offered:

Acetylcysteine (300mg) + Pyridoxamine dihydrochloride (50mg) @ 45 USD per box (150 Tablets)

So… higher price than initially shown, lower mg of PM per tablet.
Caveat Emptor

#50

Your using the wrong vendor.

#51

I looked into this further:

“When you swallow P5P, it encounters alkaline phosphatase, an enzyme bound to the membrane of your intestinal mucosa (the gut lining). This enzyme hydrolyzes the phosphate ester bond, converting the P5P back into unphosphorylated pyridoxal. Pyridoxal is then easily absorbed by cells in the small intestine via passive, carrier-mediated diffusion.
" The moment pyridoxal crosses into the intestinal cells or reaches the liver, an enzyme called pyridoxal kinase immediately attaches a new phosphate group back onto it. This turns it back into P5P.”

1 Like
#52

Exactly. This is why P5P supplements could be almost considered a scam if they are promoted as superior because they are the “active form of vitamin B6”. In reality taking P5P orally is largely like taking expensive pyridoxal.

2 Likes
#53

I looked further and found that in research studies p5p has been shown to work well in protecting against AGEs in lab rats. The doses used were 300-600 mg/kg of body weight per day. Even at the human equivilency dose that’s way too much for me. Thank you for your posts leading me to learning this.

1 Like